Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Sentynl will commercialize the Zokinvy (lonafarnib) globally. It is the first and only treatment approved by the U.S. FDA to target the cause and symptoms of progeria, also known as Hutchinson-Gilford progeria syndrome.
Lead Product(s): Lonafarnib
Therapeutic Area: Genetic Disease Product Name: Zokinvy
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Eiger BioPharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition May 03, 2024
Details:
NULIBRY (fosdenopterin) for Injection, the first therapy for the treatment of patients in Great Britain with molybdenum cofactor deficiency Type A, an ultra-rare, life-threatening genetic disorder that often progresses rapidly in infants.
Lead Product(s): Fosdenopterin
Therapeutic Area: Rare Diseases and Disorders Product Name: Nulibry
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2024